Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
Authors
Xianhai Mao
Hunan Provincial People's Hospital, Changsha, China
Xianhai Mao , Xiaohui Duan , Dongde Wu , Cuncai Zhou , Yifeng Tian , Jian Shen , Guohui Xu , Jianlin Lai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05111366
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 494)
DOI
10.1200/JCO.2024.42.3_suppl.494
Abstract #
494
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
First Author: Xianhai Mao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.
First Author: Zheng Wu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).
First Author: Changying Guo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).
First Author: Changying Guo